Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: Role of treatment duration

作者: Branka Petkovic , Gordana Stojadinovic , Srdjan Kesic , Slavica Ristic , Ljiljana Martac

DOI: 10.2298/ABS190205018P

关键词:

摘要: Paper description: Ribavirin is an antiviral agent showing side effects associated with use of high doses and/or long-term application. This study examined the single or repeated application low ribavirin (10, 20 and 30 mg/kg/day, i.p.) on dopamine-mediated behaviors, novelty-induced investigation d-amphetamine-induced motor activity, body weight gain in adult male rats. Hypolocomotion reduced a U-shaped dose-response related manner were observed after treatment. The findings contribute to improved understanding psychomotor physiological responses rodent model regard treatment duration. Abstract: Clinically-related basic studies behavioral are still lacking despite its wide as medication. paper considers mg/kg/day) activity (novelty-induced exploratory behavior, d-amphetamine (AMPH, 1.5 mg/kg, intraperitoneal)-induced activity), socially undisturbed Wistar rats 24 h first, seventh fourteenth once-a-day injection. Low tested attempt avoid recognized systemic high-dose usage. None singly applied affected exploratory/spontaneous AMPH-induced behavior (locomotion, stereotypy-like vertical however, was significantly lower mg/kg ribavirin. 7- 14-day treatments 10 mg/kg/day suppressed locomotion gain; at dose decreased stereotypy. These indicate that (up 14 days) results along gain, accentuating existence relationship prolonged duration https://doi.org/10.2298/ABS190205018P Received: February 5, 2019; Revised: March 13, Accepted: 22, Published online: 25, 2019 How cite this article: Petkovic B, Stojadinovic G, Kesic S, Ristic Martac Lj, Podgorac J, Pesic V. Psychomotor exposure rats: role Arch Biol Sci. 2019;71(2):357-68.

参考文章(44)
Laurie H. L. Sellings, Paul B. S. Clarke, Segregation of Amphetamine Reward and Locomotor Stimulation between Nucleus Accumbens Medial Shell and Core The Journal of Neuroscience. ,vol. 23, pp. 6295- 6303 ,(2003) , 10.1523/JNEUROSCI.23-15-06295.2003
P Gourde, P Harvie, R F Omar, M G Bergeron, M Tremblay, D Beauchamp, A Désormeaux, M Simard, N Dusserre, N Lansac, Ribavirin potentiates the efficacy and toxicity of 2',3'- dideoxyinosine in the murine acquired immunodeficiency syndrome model. Journal of Pharmacology and Experimental Therapeutics. ,vol. 279, pp. 1009- 1017 ,(1996)
R W Sanson-Fisher, A D Poole, J Dunn, An empirical method for determining an appropriate interval length for recording behavior. Journal of Applied Behavior Analysis. ,vol. 13, pp. 493- 500 ,(1980) , 10.1901/JABA.1980.13-493
Milena Fioravante, Sarah Monte Alegre, Daniela Miguel Marin, Sonia Leticia Silva Lorena, Tiago Sevá Pereira, Elza Cotrim Soares, Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment Nutrition. ,vol. 28, pp. 630- 634 ,(2012) , 10.1016/J.NUT.2011.08.010
Branka Janać, Vesna Pešić, Sanja Peković, Ljubisav Rakić, Mirjana Stojiljković, The time-course of ribavirin-provoked changes of basal and AMPH-induced motor activities in rats. Experimental Brain Research. ,vol. 165, pp. 402- 406 ,(2005) , 10.1007/S00221-005-2311-0
S. Kamei, T. Sakai, M. Matsuura, N. Tanaka, T. Kojima, Y. Arakawa, Y. Matsukawa, T. Mizutani, K. Oga, H. Ohkubo, H. Matsumura, K. Hirayanagi, Alterations of Quantitative EEG and Mini-Mental State Examination in Interferon-α-Treated Hepatitis C European Neurology. ,vol. 48, pp. 102- 107 ,(2002) , 10.1159/000062997
David Safronetz, Elaine Haddock, Friederike Feldmann, Hideki Ebihara, Heinz Feldmann, In Vitro and In Vivo Activity of Ribavirin against Andes Virus Infection PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0023560
E A Ferrara, J S Oishi, R W Wannemacher, E L Stephen, Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrobial Agents and Chemotherapy. ,vol. 19, pp. 1042- 1049 ,(1981) , 10.1128/AAC.19.6.1042